Linfoma de Kurkitt en un portador de granulomatosis de Wegener

Autores/as

  • Kryssia Rodríguez Castro Caja Costarricense del Seguro Social, Hospital México
  • Henry Zamora Barquero Caja Costarricense del Seguro Social, Hospital México

DOI:

https://doi.org/10.51481/amc.v47i4.209

Palabras clave:

Granulomatosis de Wegener, Linfoma de Burkitt, inmunosupresión, enfermedades linfoproliferativas

Resumen

Se reporta el caso de un paciente costarricense portador de granulomatosis de Wegener, en tratamiento con ciclofosfamida y prednisona, quien desarrolla un linfoma de Burkitt que lo lleva a la muerte. Se menciona la posible relación entre estas dos patologías.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Cos S, Harper L, Cockwell P, Adu D, Howie AJ. ABC of arterial andvascular disease: Vasculitis. BMJ 2000; 320: 1325-28.

Talar-Williams C, Hijazi YM, WM McClellan, Linehan MW,Hallahan CW, Lubensky I, Kerr GS, Hoffman GS, Fauci AS, SnellerMS. Cyclophosphamide-Induced Cystitis and Bladder Cancer inPatients with Wegener Granulomatosis Ann Intern Med, 1996; 124:477-484.

Blundell AG, Roe S. Wegener’s granulomatosis presenting as a pleu-ral effusion. BMJ, 2003; 327: 95-96.

Uppal S, Saravanappa N, Davis JP, Farmer CKT, Goldsmith DJA.Lesson of the week: Pulmonary Wegener’s granulomatosis misdiag-nosed as malignancy. BMJ, 2001; 322: 89-90. 5.Daily J P, Sadeghi S. A 35-Year-Old Man with a Painful AbdominalMass and Fever. N Engl J Med 2000; 342:493-500.

Isaacson P G. Gastrointestinal lymphomas of T- and B-cell types.Mod Pathol 1999;12:151-158.

Practice Guidelines in Oncology. National Comprehensive CancerNetwork Version 1.2005 http://www.nccn.org/professionals/physi-cian_gls/PDF/nhl.pdf

Jaffe E S. Hematopathology: Integration of morphologic features andbiologic markers for diagnosis. Mod Pathol 1999; 12:109-115.

Ramos-Casals M, Trejo O, García-Carrasco M, Cervera R, De la RedG, Gil V, López-Guillermo A, Ingelmo M, Font J. Triple AssociationBetween Hepatitis C Virus Infection, Systemic AutoimmuneDiseases, and B Cell Lymphoma. J Rheumatol 2004; 31:495-9.

Groves FD, Linet MS, Travis LB, Devesa SS. Cancer Surveillance Series: Non-Hodgkin’s Lymphoma Incidence byHistologic Subtype in the United States From 1978 Through 1995. JNatl Cancer Inst 2000; 92: 1240-1251.

Ambrus J L, Fauci A S. Diffuse histiocytic lymphoma in a patienttreated with cyclophosphamide for Wegener ́s Granulomatosis. Am JMed. 1984;76:145-747.

Colburn K K, Cao J D, Krick E H, Mortensen S E, Wong L G.Hodgkin ́s lymphoma in a patient treated for Wegener ́sGranulomatosis with cyclophosphamide and azatiophrine. JRheumatol 1985;12:599-602.

Louie S, Daoust P R, Schwartz R S. Immunodeficiency and thepathogenesis of non-Hodgkin ́s lymphoma. Semin Oncol.1980;7:267-284.

Knowles D M. Immunodeficiency-Associated lymphoproliferativedisorders. Mod Pathol 1999;12:200-217.

Thompson M P, Kurzrock R. Epstein-Barr virus and cancer. ClinCancer Res 2004,10;803-821.

Chabay P A, De Matteo E N, Aversa L, Maglio S. Grinstein S,Preciado M V. Assessment of Epstein-Barr Virus Association WithPediatric Non-Hodgkin Lymphoma in Immunocompetent and inImmunocompromised Patients in Argentina. Arch Pathol Lab Med.2002;126:331-5.

Descargas

Publicado

2005-10-01

Cómo citar

Rodríguez Castro, K., & Zamora Barquero, H. (2005). Linfoma de Kurkitt en un portador de granulomatosis de Wegener. Acta Médica Costarricense, 47(4), 199–201. https://doi.org/10.51481/amc.v47i4.209